During the past decade, Oak Clinic for Multiple Sclerosis conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 5 clinical trials were completed, i.e. on average, 500% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oak Clinic for Multiple Sclerosis" #1 sponsor was "Genzyme, a Sanofi Company" with 3 trials, followed by "EMD Serono" with 1 trials sponsored, "Fred Lublin" with 1 trials sponsored, "Mallinckrodt" with 1 trials sponsored and "Novartis" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oak Clinic for Multiple Sclerosis" #1 collaborator was "Bayer" with 3 trials as a collaborator, "Mallinckrodt ARD Inc." with 1 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Oak Clinic for Multiple Sclerosis" are "Multiple Sclerosis, Relapsing-Remitting" (4 trials), "Multiple Sclerosis" (2 trials), "Relapsing Remitting Multiple Sclerosis" (1 trials) and "Relapsing-remitting Multiple Sclerosis" (1 trials). Many other conditions were trialed in "Oak Clinic for Multiple Sclerosis" in a lesser frequency.

Most popular intervention types in "Oak Clinic for Multiple Sclerosis" are "Biological" (3 trials), "Drug" (3 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Interferon beta-1a" (2 trials), "Alemtuzumab" (1 trials), "Alemtuzumab 12 mg" (1 trials), "Alemtuzumab 24 mg" (1 trials) and "Copaxone®" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oak Clinic for Multiple Sclerosis" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Oak Clinic for Multiple Sclerosis". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Oak Clinic for Multiple Sclerosis, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Oak Clinic for Multiple Sclerosis, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".